Idenix: Cowen & Company Healthcare Conference (Idenix) - Mar 10, 2014 - "HELIX-1 Phase II Clinical Trial"; "Objectives: safety and tolerability, efficacy (primary SVR4 with supportive SVR12 and SVR 24), pharmacokinetics and pharmacodynamics, emergence of resistance"; "Well-tolerated with no treatment-related serious adverse events in the clinical trial to date"
P2 data • Hepatitis C Virus
|